Here's the regulatory secret nobody talks about: The same molecule can be a drug, supplement, medical food, device component, or cosmetic — depending on the label you put on it. Same chemistry. Same mechanism. Same patient benefit. Completely different pathway to market.

The Label Does All the Work: According to FDA guidance, regulatory classification depends on "intended use" and "claims made," not molecular structure. A peptide marketed for "supporting healthy protein synthesis" (supplement, no clinical trials) versus "treating muscle wasting" (drug, 8-year development) — identical mechanism, different regulatory universe.

Real-World Examples:

• NAD+ precursors: $500M supplement market (no FDA approval needed) vs. clinical trials for "anti-aging therapy" (10+ years)
• Collagen peptides: beauty supplement vs. wound healing biologic — same collagen, different claims
• Curcumin: spice/supplement vs. anti-inflammatory pharmaceutical

The BioDAO Opportunity: Most BioDAOs default to drug development because it sounds more prestigious. But 70% of therapeutic outcomes could be achieved through strategic relabeling for faster patient access:

1. Supplement pathway: "Supports healthy [process]" — 6 months to market
2. Medical food pathway: "Meets distinctive nutritional requirements" — 2 years
3. Device component: Physical/mechanical action — 1-2 years
4. Cosmetic ingredient: Affects appearance/structure — minimal regulation

Translation Impact: A BioDAO developing a neuroprotective compound could pursue:

• Drug route: 12 years, $500M+ development costs
• Medical food route: 3 years, $10M costs, for patients with "distinctive metabolic needs"

Same patient benefit. Different speed to market.

Strategic Reframing Exercise: Instead of asking "How do we prove this drug works?" ask "What's the fastest regulatory pathway to get this benefit to patients?" The answer might be supplement formulation, not pharmaceutical development.

The Ethical Question: Is it better to spend 12 years proving a molecule is a "drug" while patients suffer, or get meaningful benefit to them in 2 years through strategic pathway selection? Perfect shouldn't be the enemy of helpful.

Evidence-Based Regulation: Many supplements have stronger clinical evidence than approved drugs. FDA doesn't require supplements to be ineffective — they just can't claim to treat diseases. But patients can research and choose based on published studies.

The Translation Challenge: Can we achieve 70% of therapeutic outcome through 20% of regulatory complexity? For most BioDAO programs, the answer is yes — if they optimize for speed to patient benefit rather than regulatory prestige.

Sometimes the fastest way to help patients isn't through the front door.